Q2BI
Q2BI is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)
Sponsor Vera Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)
Sponsor C4 Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients with IgAN
Sponsor Vera Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Q2BI?
The 2026-10-09 snapshot links Q2BI to 3 distinct CTIS trials. Recorded services include Statistical analysis, Data management, Programming, Third party managing EDC vendor. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Q2BI?
The most frequently recorded therapeutic areas are Haematological Malignancies, Immunology, Nephrology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Q2BI conducted?
The linked trials record locations in 6 countries, including Spain, Poland, France, Italy, Belgium. These are trial locations, not confirmed office locations or countries where Q2BI delivered services.
What can this page tell me about Q2BI's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Q2BI. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Q2BI Corp.